Cannabics Pharmaceuticals, Inc. (CNBX) Achieves GMP Compliance, Announces Preparation of Clinical Study
Cannabics Pharmaceuticals today announced that it has attained Good Manufacturing Practices (GMP) capabilities. Additionally, the company reported it is moving toward the launch of its first clinical study of Cannabics SR capsules.
GMP regulations are designed to ensure that products are produced and controlled according to quality standards. Adhering to these practices ranks Cannabics’ products among a very limited number of medical cannabis products available in the U.S. market that are manufactured according to GMP standards.
Cannabics’ Chief Technology Officer Dr. Eyal Ballan stated, “We’re proud to announce GMP standing as we prepare for the upcoming launch of our Cannabics SR capsules. We have developed a product with incredible potential in the oncology market and aim to maintain product integrity throughout the entire manufacturing process.”
Cannabics plans to launch a number of clinical studies in leading medical centers in Israel where the company’s R&D division is strategically located. The company is on track to become one of the first and few companies to commercialize clinically tested cannabis-based products.
“Cannabics SR, our first market ready product, was developed and designed specifically as a palliative therapy for oncology patients,” commented Dr. Ballan. “We are still developing a broad pipeline of additional cannabis based products designed for various indications such as Neuropathic pain, inflammatory bowel disease, post trauma stress syndrome, CNS degenerative disorders and more. Each of these products will be tested in comprehensive and formal clinical studies to prove its efficacy and safety.”
Cannabics emphasized that its products will have a strong advantage over competing medical cannabis products in the market. In addition to the superior pharmacokinetic profile of the Cannabics SR formulations, the company will have clinical results of the efficacy and safety data collected in these formal post-marketing studies.
Cannabics intends to market Cannabics SR capsules under the current medical cannabis regulations in the United States, Europe and Israel. Based on a proprietary formulation that contains only certified food ingredients, Cannabics SR capsules will be marketed as a “cannabis-infused edible product” and will be available to certified and registered patients.
In previous observational studies, Cannabics SR capsules has been shown to provide 10-12 hours of reduced nausea and pain while promoting appetite for cancer patients. These capsules are taken only one to two times a day. Also, because they are taken orally as capsules, patients avoid the long-term harmful effects of smoking cannabis.
“Cannabics SR capsules answer a considerable unmet need to alleviate the discomforts of oncology patients without the health hazards associated with smoking cannabis for palliative purpose,” stated Dr. Ballan. “To date, more than 100 patients in Israel (most of them oncology patients) have already been treated with Cannabics SR capsules. The positive responses and high satisfaction level of patients and doctors with this cannabis based therapy option has been overwhelming.”
For more information, visit www.cannabics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com